Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-03-27
2010-10-19
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S052000
Reexamination Certificate
active
07816339
ABSTRACT:
The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.
REFERENCES:
patent: 3853845 (1974-12-01), Rousseau et al.
patent: 4542021 (1985-09-01), Kodama et al.
patent: 4659825 (1987-04-01), Holy et al.
patent: 4812560 (1989-03-01), Terada et al.
patent: 4879214 (1989-11-01), Kornher et al.
patent: 4927966 (1990-05-01), Kalman
patent: 5010103 (1991-04-01), Kalman
patent: 5049663 (1991-09-01), Terada et al.
patent: 5051498 (1991-09-01), Kalman
patent: 5512298 (1996-04-01), Aoki et al.
patent: 5646269 (1997-07-01), Matteucci et al.
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5886162 (1999-03-01), Kalman
patent: 5889015 (1999-03-01), Sequeira et al.
patent: 6147058 (2000-11-01), Yoshimura et al.
patent: 6277830 (2001-08-01), Ganguly et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6346379 (2002-02-01), Gelfand et al.
patent: 6472373 (2002-10-01), Albrecht
patent: 6545007 (2003-04-01), Sommadossi et al.
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 6599914 (2003-07-01), Schleimer et al.
patent: 7524831 (2009-04-01), Malcolm et al.
patent: 2002/0151536 (2002-10-01), Davis et al.
patent: 2002/0198171 (2002-12-01), Schinazi et al.
patent: 2003/0203872 (2003-10-01), Secrist, III et al.
patent: 2003/0225029 (2003-12-01), Stuyver
patent: 2003/0235582 (2003-12-01), Singh et al.
patent: 2004/0110718 (2004-06-01), Devos et al.
patent: 2004/0265307 (2004-12-01), Singh et al.
patent: 0239015 (1991-10-01), None
patent: 0902035 (1999-03-01), None
patent: 0563697 (2001-07-01), None
patent: 1469577 (1977-04-01), None
patent: 52-065281 (1977-05-01), None
patent: 53-141284 (1978-12-01), None
patent: 55-049588 (1980-04-01), None
patent: 6-206822 (1994-07-01), None
patent: 6-206822 (2004-07-01), None
patent: WO 94/21658 (1994-09-01), None
patent: WO 95/29930 (1995-11-01), None
patent: WO 99/45016 (1999-09-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 01/14345 (2001-03-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/60315 (2001-08-01), None
patent: WO 01/90121 (2001-11-01), None
patent: WO 01/92282 (2001-12-01), None
patent: WO 01/96353 (2001-12-01), None
patent: WO 02/18404 (2002-03-01), None
patent: WO 02/053138 (2002-07-01), None
patent: WO02/53138 (2002-07-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/083126 (2002-10-01), None
patent: WO 02/094289 (2002-11-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 03/026589 (2003-04-01), None
patent: WO 03/026675 (2003-04-01), None
patent: WO 03/051896 (2003-06-01), None
patent: WO 03/062255 (2003-07-01), None
patent: WO 03/062256 (2003-07-01), None
patent: WO 03/106621 (2003-12-01), None
patent: WO 2004/002422 (2004-01-01), None
patent: WO 2004/046331 (2004-06-01), None
Bartenschlager, In vitro models for hepatitis C. Virus Res. Jan 30, 2002;82(1-2):25-32.
Bartenschlager, Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov. Nov. 2002;1(11):911-6.
Beisler et al., Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine. J Med Chem. Jun. 1977;20(6):806-12.
Bellet et al., Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study). Neoplasma. 1973;20(3):303-9. No abstract available.
Brachwitz et al., 1-beta-D-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C. J Lipid Res. Jan. 1998;39(1):162-72.
Braess et al., Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma—phase I/II studies and pharmacokinetics. Leukemia. Oct. 1998;12(10):1618-26.
Cadman et al., Clinical, biological, and biochemical effects of pyrazofurin. Cancer Res. Mar. 1978;38(3):682-8.
Debernardo et al., Synthesis of oxazinomycin (minimycin). J Org Chem. Jan. 7, 1977;42(1):109-12.
Diamond et al., Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA, Virology 304:211-221 (2002).
Dix et al., Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells, Cancer Res. Nov. 1979;39(11):4485-90.
Endresen et al., Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. Scand J Rheumatol. 2001;30(3):129-34.
Formann et al., Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepat. Jul. 2003;10(4):271-6.
Hamada et al., Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705-18.
Harrap et al., Intracellular nucleotide pools and their significance in antimetabolite therapy. Antibiot Chemother. 1980;28:68-77.
Haspel et al., Temperature-sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination. Proc Natl Acad Sci U S A. Aug. 1978;75(8):4033-6.
Higashigawa et al., Deoxyribonucleoside triphosphate pools and Ara-CTP levels in P388 murine leukemic cells treated with 1-B-D-arabinofuranosylcytosine-5′-stearylphosphate which is a newly synthesized derivative of 1-B-D-arabinofuranosylcytosine. Med Oncol Tumor Pharmacother. 1990;7(4):223-6.
Hirota et al., Regioselective BH3-hydride reduction of inosine derivatives, Tetrahedron Letters (2002) 43: 653-655.
Kerr et al., Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analogue 2′,3′-dideoxycytidine and its 3′-fluoro derivative. J Med Chem. May 29, 1992;35(11):1996-2001.
Kerr et al., N4-(dialkylamino)methylene derivatives of 2′-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications. J Pharm Sci. Apr. 1994;83(4):582-6.
Kodama, K. et al., Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine. Jpn J Cancer Res. Jul. 1989;80(7):679-85. Erratum in: Jpn J Cancer Res May 1990;81(5):544.
Kreutzer et al., Oxidized, deaminated cytosines are a source of C→ T transitions in vivo. Proc Natl Acad Sci U S A. Mar. 31, 1998;95(7):3578-82.
Krieger et al., Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol. May 2001;75(10):4614-24.
Kuhr et al., Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study. Leuk Res. Jul. 2000;24(7):583-7.
P.Kong Thoo Lin et al., Synthesis and duplex stability of oligonucleotides containing cytosine-thymine analogues. Nucleic Acids Res. (1985) 17(24): 10373-10383.
Loeb et al., Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retroviruses. Jan. 1, 2000;16(1):1-3.
Loeb et al., Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A. Feb. 16, 1999;96(4):1492-7.
Maloisel F. et al., Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia. Apr. 2002;16(4):573-80.
Markland, W. et al., Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. Apr. 2000;44(4):859-66.
McCormick, Patrick J. et al., Changes in ribo- and deoxyribonucleoside triphosphate pools within the cell cycle of a synchronized mouse fibroblast cell line. Biochim Biophys Acta. Mar. 15, 1983;755(1):36-40.
Meyerhans, Andreas et al., Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol. Jan. 1994;68(1):535-40.
Moriyama, K. et al., Highly efficient random mutagenesis in transcription-reverse-transcription cycles by a hydrogen bond ambivalent nucleoside 5′-triphosphate
Feld Boris
Le Hung
Malcolm Bruce A.
Palermo Robert
Tong Xiao
McIntosh, III Traviss C
Schering Corporation
LandOfFree
Treatments for Flaviviridae virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatments for Flaviviridae virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatments for Flaviviridae virus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225032